SCHEMBL13720446

SCHEMBL13720446

O=C(Cc1ccc(Cl)cc1)Nn1nc(S(=O)(=O)c2ccncc2)c2ccccc2c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ KMT2A Q03164 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ ABCB1 P08183 1/20 0.42
▸ EGFR P00533 2/20 0.42
▸ ERBB2 P04626 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ NAMPT P43490 2/20 0.40
▸ CACNA1G O43497 1/20 0.40
▸ CACNA1H O95180 1/20 0.40
▸ CACNA1I Q9P0X4 1/20 0.40
▸ YES1 P07947 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ JAK3 P52333 1/20 0.39
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13721332 0.93 EGFR (0.50) KDM4EHPGDKMT2AMEN1ABCB1
SCHEMBL13720804 0.89 EGFR (0.50) KDM4EHPGDKMT2AMEN1EGFR
SCHEMBL13858680 0.89 KDM4E (0.45) KDM4EHPGDKMT2AMEN1ABCB1
SCHEMBL13720284 0.89 EGFR (0.50) KDM4EHPGDKMT2AMEN1NPC1
SCHEMBL13720542 0.89 KDM4E (0.45) KDM4EHPGDKMT2AMEN1EGFR
SCHEMBL13720857 0.87 KDM4E (0.43) KDM4EHPGDKMT2AMEN1EGFR
SCHEMBL16155987 0.86 PRMT1 (0.46) KDM4EHPGDKMT2AMEN1EGFR
SCHEMBL13720642 0.86 ABCB1 (0.48) KDM4EHPGDKMT2AMEN1ABCB1
SCHEMBL13720504 0.82 KDM4E (0.48) KDM4EHPGDKMT2AMEN1EGFR
SCHEMBL13720678 0.82 KDM4E (0.46) KDM4EHPGDKMT2AMEN1ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859549-B2 Potassium channel modulators ABBVIE, INC. (US) 2014-10-14 — — US claimed
WO-2012158399-A1 CONDENSED 2 - CARBAMOYLPYRIDAZINONES AS POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-11-22 — — WO claimed
US-20120289500-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-11-15 — — US claimed
US-8859549-B2 Potassium channel modulators ABBVIE, INC. (US) 2014-10-14 — — US disclosed
WO-2012158399-A1 CONDENSED 2 - CARBAMOYLPYRIDAZINONES AS POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-11-22 — — WO disclosed
US-20120289500-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289500-A1 POTASSIUM CHANNEL MODULATORS KCNQ1, KCNQ2, KCNJ2 KDM4E 751/4885HPGD 1562/4885KMT2A 574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback